Ambry Genetics ProstateNext Panel

Ambry Genetics has launched its ProstateNext 14-gene panel for hereditary prostate cancer. The panel evaluates germline ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51D, and TP53 genes using next-generation sequencing and deletion/duplication analysis to determine disease risk and/or treatment options.